
Citofer210 mg
Incepta Pharmaceuticals Ltd.
Established / FDA-Approved Uses Control of serum phosphorus levels in adult patients with chronic kidney disease (CKD) who are on dialysis (hemodialysis or peritoneal dialysis).
Ferric Citrate has two distinct, FDA-approved indications depending on the clinical context (phosphate control on dialysis vs. anemia treatment off dialysis), and the dosing target differs accordingly (serum phosphorus vs. hemoglobin).
| Indication | Starting Dose | Titration | Maximum |
|---|---|---|---|
| Hyperphosphatemia in CKD on dialysis | 2 tablets orally three times daily with meals | Adjust in increments of 1-2 tablets/day at intervals of ≥1 week, based on serum phosphorus levels | 12 tablets/day |
| Iron deficiency anemia in CKD not on dialysis | 1 tablet orally three times daily with meals | Adjust in increments of 1-2 tablets/day at intervals of ≥1 week, based on hemoglobin response | 12 tablets/day |
Dose adjustments and monitoring (serum phosphorus for the dialysis indication; hemoglobin, ferritin, and transferrin saturation for the anemia indication) should be guided by a physician.
The most common side effects of Ferric Citrate are gastrointestinal and generally dose-related, often improving with continued use:
Iron overload (elevated ferritin/transferrin saturation) can occur with excessive intake - see Contraindications and Precautions.
Ferric Citrate is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.